CD44 and breast cancer: Likewise, the study of Magoling et al. showed that depletion of CD44 on EVs derived from breast cancer cells significantly reduced their in vivo tumor delivery, which was evidenced by reduced tumor growth, thus highlighting the role of CD44 on TEVs surface in modulating their organotropism [119].